EP3989949A4 - Inhibitors of prc1 for treatment of cancer - Google Patents

Inhibitors of prc1 for treatment of cancer Download PDF

Info

Publication number
EP3989949A4
EP3989949A4 EP20830832.0A EP20830832A EP3989949A4 EP 3989949 A4 EP3989949 A4 EP 3989949A4 EP 20830832 A EP20830832 A EP 20830832A EP 3989949 A4 EP3989949 A4 EP 3989949A4
Authority
EP
European Patent Office
Prior art keywords
prc1
inhibitors
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20830832.0A
Other languages
German (de)
French (fr)
Other versions
EP3989949A1 (en
Inventor
Filippo Giancotti
Ouathek Ouerfelli
Wenjing Su
Guangli Yang
Howard Scher
Mohammad Marzabadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Memorial Sloan Kettering Cancer Center
Original Assignee
University of Texas System
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Memorial Sloan Kettering Cancer Center filed Critical University of Texas System
Publication of EP3989949A1 publication Critical patent/EP3989949A1/en
Publication of EP3989949A4 publication Critical patent/EP3989949A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
EP20830832.0A 2019-06-27 2020-06-26 Inhibitors of prc1 for treatment of cancer Pending EP3989949A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867760P 2019-06-27 2019-06-27
PCT/US2020/039896 WO2020264348A1 (en) 2019-06-27 2020-06-26 Inhibitors of prc1 for treatment of cancer

Publications (2)

Publication Number Publication Date
EP3989949A1 EP3989949A1 (en) 2022-05-04
EP3989949A4 true EP3989949A4 (en) 2023-07-12

Family

ID=74061457

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20830832.0A Pending EP3989949A4 (en) 2019-06-27 2020-06-26 Inhibitors of prc1 for treatment of cancer

Country Status (4)

Country Link
US (1) US20220257601A1 (en)
EP (1) EP3989949A4 (en)
CA (1) CA3145232A1 (en)
WO (1) WO2020264348A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064396A2 (en) * 2010-08-21 2012-05-18 Georgetown University Novel ezrin inhibitors and methods of making and using

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan Compositions and methods for treating and diagnosing cancer
EP1891434B1 (en) * 2005-06-02 2011-01-05 The University of North Carolina at Chapel Hill Purification, characterization and reconstitution of a ubiquitin e3 ligase
CA2905070A1 (en) * 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US10900036B2 (en) * 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
US20190338290A1 (en) * 2017-01-16 2019-11-07 Memorial Sloan Kettering Cancer Center Treatment of sarcoma
US20200347456A1 (en) * 2017-10-02 2020-11-05 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US11319302B2 (en) * 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064396A2 (en) * 2010-08-21 2012-05-18 Georgetown University Novel ezrin inhibitors and methods of making and using

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BORKENT J.H. ET AL: "Fluorescence from inter- and intramolecular charge-transfer complexes", TETRAHEDRON LETTERS, vol. 13, no. 32, 1 January 1972 (1972-01-01), Amsterdam , NL, pages 3363 - 3366, XP093050400, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(01)94046-8 *
CRAENEN, H. A. H., VERHOEVEN, J. W., DE BOER, TH. J.: "Inter- and intramolecular donor-acceptor interactions. X. Intramolecular charge transfer interaction in substituted N-aralkylphthalimides and -1,8-naphthalimides", RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS, vol. 91, no. 3, 1 January 1972 (1972-01-01), pages 405 - 416, XP009544686 *
DENNY W A ET AL: "Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 25, no. 3, 1 March 1982 (1982-03-01), pages 276 - 315, XP002619868, ISSN: 0022-2623, DOI: 10.1021/JM00345A015 *
GOLUB ET AL: "Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, vol. 1784, no. 1, 20 November 2007 (2007-11-20), pages 143 - 149, XP022425230, ISSN: 1570-9639, DOI: 10.1016/J.BBAPAP.2007.10.009 *
HIRATA YOKO ET AL: "Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22?cells", NEUROPHARMACOLOGY, vol. 135, 1 June 2018 (2018-06-01), AMSTERDAM, NL, pages 242 - 252, XP093050451, ISSN: 0028-3908, DOI: 10.1016/j.neuropharm.2018.03.015 *
I. H. ISMAIL ET AL: "A Small Molecule Inhibitor of Polycomb Repressive Complex 1 Inhibits Ubiquitin Signaling at DNA Double-strand Breaks", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 37, 30 July 2013 (2013-07-30), US, pages 26944 - 26954, XP055373042, ISSN: 0021-9258, DOI: 10.1074/jbc.M113.461699 *
PRESSER ARMIN ET AL: "Synthesis of Jacaranone-Derived Nitrogenous Cyclohexadienones and Their Antiproliferative and Antiprotozoal Activities", MOLECULES, vol. 23, no. 11, 7 November 2018 (2018-11-07), DE, pages 2902, XP093050411, ISSN: 1433-1373, DOI: 10.3390/molecules23112902 *
See also references of WO2020264348A1 *

Also Published As

Publication number Publication date
CA3145232A1 (en) 2020-12-30
US20220257601A1 (en) 2022-08-18
WO2020264348A1 (en) 2020-12-30
EP3989949A1 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
EP3781564A4 (en) Compounds for the treatment of cancer
EP3464643A4 (en) Use of ezh2 inhibitors for treating cancer
EP3782618A4 (en) Method for preventing or treating side effects of cancer therapy
EP3787625A4 (en) Methods of treating cancer
EP4085053A4 (en) Treatment of cancer with cdk12/13 inhibitors
EP3982949A4 (en) Inhibitors of sarm1
EP3980011A4 (en) Inhibitors of sarm1
EP4010081A4 (en) Combination therapy for treatment of cancer
EP3630080A4 (en) Use of ezh2 inhibitors for treating cancer
EP3908650A4 (en) Methods of treating cancer
EP3758678A4 (en) Methods of treatment of cancer comprising chk1 inhibitors
IL288522A (en) Egfr inhibitor for the treatment of cancer
IL288665A (en) Methods of treating cancer using prmt5 inhibitors
EP3947460A4 (en) Multispecific agents for treatment of cancer
EP3856352A4 (en) Methods of treatment of cancer comprising cdc7 inhibitors
EP3893882A4 (en) Cxcr7 inhibitors for the treatment of cancer
EP3946419A4 (en) Methods of treating cancer with chk1 inhibitors
EP3952858A4 (en) Method of treating tumours
EP3949966A4 (en) Chiauranib for treatment of small cell lung cancer
EP3793548A4 (en) Compounds for treatment of pancreatic cancer
EP3852816A4 (en) Methods of treating cancer
EP3781215A4 (en) Methods of treating cancer
AU2022231043A1 (en) Chaperonin-containing tcp-1 inhibitors for the treatment of cancer
EP4072561A4 (en) Methods of treating cancer
IL289201A (en) Compounds for treatment of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031000000

Ipc: C07D0209480000

A4 Supplementary search report drawn up and despatched

Effective date: 20230612

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20230605BHEP

Ipc: A61P 43/00 20060101ALI20230605BHEP

Ipc: A61P 35/00 20060101ALI20230605BHEP

Ipc: A61K 45/06 20060101ALI20230605BHEP

Ipc: A61K 39/395 20060101ALI20230605BHEP

Ipc: A61K 31/00 20060101ALI20230605BHEP

Ipc: C07D 209/48 20060101AFI20230605BHEP